DOCSLIB.ORG

Pharmacokinetic Evaluation of Amoxicillin/Clavulanicacid And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacokinetic Evaluation of Amoxicillin/Clavulanicacid And PHARMACOKINETIC EVALUATION OF AMOXICILLIN/CLAVULANICACID AND ANTACID INTERACTION Anab Fatima B.Pharm, M.Phil.(Pharmaceutics) Thesis submitted for the award of degree of Ph.D In Pharmaceutics DEPARTMENT OF PHARMACEUTICS FACULTY OF PHARMACY UNIVERSITY OF KARACHI. 1 2 In the name of ALLAH The most Beneficient and tha most Merciful………………. ALLAHUMA SALLEY ALA SYEDENA MAULANA MUHAMMEDUN WA ALA AALEHYY WA ASHABHI BARIK WASALLIM WA SALLO ALEHEY SURAT AL-FATIHAH 1. IN THE NAME OF ALLAH,THE MOST GRACIOUS,THE MOST MERCIFUL. 3 2. ALL THE PRAISES AND THANKS BE TO ALLAH,THE LORD OF THE A LAMIN(MANKIND,JINN AND ALL THAT EXIST). 3. THE MOST GRACIOUS,THE MOST MERCIFUL. 4. THE ONLY OWNER(AND THE ONLY RULING JUDGE)OF THE DAY OF RECOMPENSE(THE DAY OF RESURRECTION). 5. YOU(ALONE) WE WORSHIP,AND YOU(ALONE) WE ASK FOR HELP(FOR EACH AND EVERY THING). 6. GUIDE US TO STRAIGHT WAY. 7. THE WAY OF THOSE WHOM YOU HAVE BESTOWED YOUR GRACE,NOT(THE WAY) OF THOSE WHO EARNED YOUR ANGER NOR OF THOSE WHO WENT ASTRAY.(AAMEEN) 4 DEDICATED TO: My beloved Parentral Grand Father(late),Grand Mother(late),Parents and all those persons whose prayers bring me to this stage. ACKNOWLEDGEMENT “If ALLAH assist you, then there is none that can overcome you” (Holy Quran 3:160) All praise to Almighty Allah who gives me strength, confidence and courage to complete the thesis. I am heartiest thankful to my research supervisor Prof.Dr.S.Baqir.S.Naqvi for his valuable guidance, sincere advice, moral support and encouragement throughout the research project. He was really much helpful during research work for managing expensive chemicals and accessories for rapid completion of the project. • I am really so much thankful to Dr.Rabia Ismail Yousuf and Mrs.Rehana Saeed Assistant Professor Department of Pharmaceutics, University of Karachi for their kind and humble cooperation throughout my research project. 5 • I am also thankful to Dr. Mohammed Harris Shoaib, Mrs. Sabahat jabeen,Mr.Iyad Naeem,Dr.Shaista Assistant Professors and Ms.Fauzia Israr lecturer Department of Pharmaceutics,Faculty of Pharmacy,University of Karachi for their sincere suggestions and help whenever required during this research project. • Worthful acknowledgement to Prof.Dr.Dilnawaz Sheikh and Prof.Dr.Rafi Sheikh for their resilient support and reinforcement during the research work. • Special thanks to Prof.Dr. Javeid Iqbal Dean ,Faculty of Pharmacy,Hamdard University for his co-operation and valuable suggestions during my research project. • I am also thankful to each and every teacher including Prof.Dr.Fauzia, Prof.Dr.Nighat and Dr.Shahnaz for providing me knowledge in any way. • I appreciated all non-teaching staff of department of Pharmaceutics,University of Karachi for their co-operation during this work. • Thanks to my friend Miss. Shaheen Parveen who sincerely encouraged me during my research work. • I am also obliged to library incharge Mr.Azhar for providing me books during this research work. • I am thankful to Mr.Amjad and their Lab staff of Liaqat National Hospital for providing me plasma for my research. • I am so much thankful to Mr. Jibran and Mr.Ilyas from Imam Clinic for helping me to provide plasma from Husaini blood bank and for conducting my clinical study at Imam Clinic. • I am also indebted to whole administration of Imam Clinic including Dr.Ali Imam, Dr.Noman Palekar, Dr.Hisala and other HR and nursing staff for their humble Cooperation during my clinical study. • I am also thankful to Dr.Sajjad, Mr.Ghulam Abbas, Mr.Asim of Dr.Tahir Shamsi lab and Mr.Ayaz from Hamdard University for providing their support and help in sampling of blood during my study. • I am really thankful to Dr.Tanveer Abbas, Assistant Professsor department of Microbiology,University of Karachi for telling me useful links for literature survey. • Special thanks for my parents prayers that gave me strength during my work without which this work would not be completed. • Special thanks for my all family members especially my brothers Sheikh Abdul Khaliq,Sheikh Abdul Rehman and Sheikh Mohammed Jiyad for their kind cooperation during my research project. • I sincerely acknowledge and appreciate those volunteers namely Farrukh Najam, Mehdi Raza, Syed Zaad Ali, Mohammed Rafiq, Mohammed Asif Basheer, Syed Mohammed Mohsin Rizvi, Mohammed Uzair Shah, Waqas Ali, Adil Waqas and H.M.Bilal Anjum who participated in this research project. • Words for those who helped me in any way for the completion of this research work. 6 May ALLAH Bless Them All.(Aameeen) TABLE OF CONTENTS ABSTRACT……………………………………………………………………………………. KHULASA……………………………………………………………………………………… 1.INTRODUCTION……………………………………………………………………………..1 1.1 Drug Interaction……………………………………………………………………………...2 1. 2.Drug-Drug Interactions(DDIs)……………………………………………………………...3 1.3. Pharmacokinetic Determination of Drug-Drug Interactions…………..9 1.4. Pharmaceutical analysis of drugs in dosage forms……………………..10 1.5. ANALYSIS OF ANTIBIOTIC USING HPLC…………………….…12 1.6. HISTORY/STORY OF PENICILLIN…………………………………14 1.6.4. PHARMACOKINETIC OF PENICILLIN…………………………………………..17 7 1.6.5. AMOXICILLIN/CLAVULANIC ACID(AUGMENTIN)……………………………18 2. OBJECTIVE OF THE STUDY……………………………………………………26-27 3. LITERATURE REVIEW…………………………………………………………..28-62 4. EXPERIMENTAL……………………………………………………………………...63 4.1.PHYSICO-CHEMICAL TESTS OF DIFFERENT CO-AMOXICLAV BRANDS…….64 4.1.1. WEIGHT VARIATION TEST………………………………………………………..64 4.1.2 THICKNESS VARIATION TEST……………………………………………………65 4.1.3. HARDNESS TEST…………………………………………………………………….65 4.1.4. DISINTEGRATION TEST……………………………………………………………65 4.1.5. DISSOLUTION TEST…………………………………………………………………65 4.1.6. CONTENT ASSAY FOR CO-AMOXICLAV TABLETS BY HPLC………………67 4.2. PHARMACOKINETIC EVALUATION OF CO-AMOXICLAV TABLET……..68 4.3. Validation Parameters………………………………………………………………….74 4.4. System suitability parameters………………………………………………………….74 4.4.1. Specificity ……………………………………………………………………………….74 4.4.2. Linearity…………………………………………………………………………………74 4.4.3. Intra-Day and Inter-Day Accuracy and Precision……………………………………74 4.4.4. Lower Limit of Quantification (LLOQ) and Limit of Detection (LOD)…………….75 4.4.5. Recovery…………………………………………………………………………………75 4.4.6. Stability………………………………………………………………………………….75 4.4.7. Freeze and Thaw stability……………………………………………………………...75 4.4.8. Long Term Stability…………………………………………………………………….76 8 4.5. Pharmacokinetic Analysis……………………………………………………………...76 4.5.1. Compartmental…………………………………………………………………………76 4.5.2. Non-Compartmental……………………………………………………………………76 4.7. SERUM BACTERICIDAL TEST (SBT)…………………………………………….77 5.RESULTS…………………………………………………………………………………80- 139 % RELATIVE BIO-AVAILABILITY………………………………………………………161 7.DISCUSSION……………………………………………………………………………162- 177 8.REFERENCES …………………………………………………………………………230-245 9.APPENDIX…………………………………………………………………………………..246 NATIONAL BIOETHICS COMMITTEE(NBC) PAK ISTAN APPROVAL…………..247 PUBLICATION FROM RESEARCH WORK……………………………………………..248 LIST OF PUBLICATIONS……………………………………………………………..........249 LIST OF TABLES TABLE 1……………………………………………………………………………………6 & 7 THE MOST DANGEROUS DRUG INTERACTION.……………………………………………………………………………6 & 7 TABLE 2………………………………………………………………………………………...83 DETAILS OF DIFFERENT AMOXICILLIN/CLAVULANIC ACID PRODUCTS AVAILABLE IN PAKISTAN………………………………………………………………….83 TABLE 3………………………………………………………………………………………...84 9 WEIGHT VARIATION TEST OF AMOXICILLIN/CLAVULANIC ACID BRANDS AVAILABLE IN PAKISTAN………………………………………………………………….84 TABLE 4…………………………………………………………………………...……………86 THICKNESS VARIATION TEST OF AMOXICILLIN/CLAVULANIC ACID BRANDS AVAILABLE IN PAKISTAN………………………………………………………………….86 TABLE 5………………………………………………………………………………………...87 HARDNESS VARIATION TEST OF AMOXICILLIN/CLAVULANIC ACID BRANDS AVAILABLE IN PAKISTAN…………………………………………………………………87 TABLE 6………………………………………………………………………………………...90 DISSOLUTION OF DIFFERENT BRANDS OF AMOXICILLIN/CLAVULANIC ACID TABLET(250/125 mg) AVAILABLE IN PAKISTAN……………………………………….90 TABLE 7………………………………………………………………………………………91 HPLC ASSAY OF DIFFERENT BRANDS OF AMOXICILLIN/CLAVULANIC ACID TABLET(250/125 mg) AVAILABLE IN PAKISTAN…………………………………….....91 TABLE 8(a)……………………………………………………………………………………..92 CALIBRATION CURVE OF AMOXICILLIN STD in Human Plasma(Linearity,Accuracy and Precision)…………………………………………………92 TABLE 8(b)…………………………………………………………………………………….93 Back Calculated Concentration of Amoxicillin Standard in Human Plasma……………..93 TABLE 9(a)……………………………………………………………………………………..96 CALIBRATION CURVE OF CLAVULANIC ACID STD in Human Plasma (Linearity, Accuracy and Precision)………………………………………………………………………..96 TABLE 9(b)…………………………………………………………………………………….97 Back Calculated Concentration of Clavulanic Acid Standard in Human Plasma………97 TABLE 10(a)…………………………………………………………………………………100 INTRA-DAY PRECISION AND ACCURACY OF AMOXICILLIN IN HUMAN PLASMA(n=3)………………………………………………………………………………...100 TABLE 10(b)…………………………………………………………………………………..100 10 INTRA-DAY PRECISION AND ACCURACY OF CLAVULANIC ACID IN HUMAN PLASMA(n=3)……………………………………………………………………...…………100 TABLE 11(a)……………………………………………………………………………...101-102 INTER-DAY PRECISION AND ACCURACY OF AMOXICILLIN IN HUMAN PLASMA(n=5)……………………………………………………………………………101-102 TABLE 11(b)……………………………………………………………………………...103-104 INTER-DAY PRECISION AND ACCURACY OF CLAVULANIC ACID IN HUMAN PLASMA(n=5)…………………………………...……………………………………….103-104 TABLE 12(a)…………………………………………………………………………………..105 LOWER LIMIT OF QUANTIFICATION (LLOQ) FOR AMOXICILLIN……………..105 TABLE 12(b)…………………………………………………………………………………..106 Back Calculated Concentration of Amoxicillin……………………………………………..106 TABLE 13(a)…………………………………………………………………………………..107 LOWER LIMIT OF QUANTIFICATION (LLOQ) FOR CLAVULANIC ACID………107
Load more

Recommended publications
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Cephalosporin Administration to Patients with a History of Penicillin Allergy Adverse Reactions to Drugs, Biologicals and Latex Committee
    Work group report May, 2009 Cephalosporin Administration to Patients with a History of Penicillin Allergy Adverse Reactions to Drugs, Biologicals and Latex Committee Work Group Members : Roland Solensky, MD FAAAAI, Chair Aleena Banerji, MD Gordon R. Bloomberg, MD FAAAAI Marianna C. Castells, MD PhD FAAAAI Paul J. Dowling, MD George R. Green, MD FAAAAI Eric M. Macy, MD FAAAAI Myngoc T. Nguyen, MD FAAAAI Antonino G. Romano, MD PhD Fanny Silviu-Dan, MD FAAAAI Clifford M. Tepper, MD FAAAAI INTRODUCTION Penicillins and cephalosporins share a common beta-lactam ring structure, and hence the potential for IgE-mediated allergic cross-reactivity. Allergic cross-reactivity between penicillins and cephalosporins potentially may also occur due to presence of identical or similar R-group side chains, in which case IgE is directed against the side chain, rather the core beta-lactam structure. This work group report will address the administration of cephalosporins in patients with a history of penicillin allergy. First, published data will be reviewed regarding 1) cephalosporin challenges of patients with a history of penicillin allergy (without preceding skin testing or in vitro testing), and 2) cephalosporin challenges of patients proven to have a type I allergy to penicillins (via positive penicillin skin test, in vitro test or challenge). Secondly, 1 2/9/2011 recommendations on cephalosporin administration to patients with a history of penicillin allergy will be presented. Unless specifically noted, the term ‘penicillin allergy’ will be used to indicate an allergy to one or more of the penicillin-class antibiotics, not just to penicillin itself. The following discussion includes references, in certain clinical situations, to performing cephalosporin graded challenges in patients with a history of penicillin allergy.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Directed Molecular Evolution of Fourth-Generation Cephalosporin Resistance in Wellington Moore Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Directed molecular evolution of fourth-generation cephalosporin resistance in Wellington Moore Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Medical Sciences Commons Recommended Citation Moore, Wellington, "Directed molecular evolution of fourth-generation cephalosporin resistance in" (2011). Graduate Theses and Dissertations. 10107. https://lib.dr.iastate.edu/etd/10107 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Directed molecular evolution of fourth-generation cephalosporin resistance in Salmonella and Yersinia by Wellington Moore A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Biomedical Science (Pharmacology) Program of Study Committee: Steve Carlson, Major Professor Timothy Day Ronald Griffith Iowa State University Ames, Iowa 2011 ii TABLE OF CONTENTS LIST OF FIGURES………………………………………………………………………iii LIST OF TABLES………………………………………………………………………..iv ABSTRACT……………………………………………………………………………….v CHAPTER 1. INTRODUCTION…………………………………………………………1 Review of B-Lactam antimicrobials………………………………...………1
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,763,603 Trickes 45 Date of Patent: Jun
    USOO5763603A United States Patent 19 11 Patent Number: 5,763,603 Trickes 45 Date of Patent: Jun. 9, 1998 54 CRYSTALLINE TAZOBACTAM, AND ITS 4,912,211 3/1990 Bonfanti................................. 540/222 PRODUCTION AND USE FOREIGN PATENT DOCUMENTS (75) Inventor: Georg Trickes, Loerrach, Germany 63-66187 3/1988 Japan. 73) Assignee: Taiho Pharmaceutical Co., Ltd., OTHER PUBLICATIONS Tokyo, Japan Chemical Patents Index Basic Abstracts Journal, Section (21) Appl. No.: 403829 B:FARMDOC, 1988, Derwent Publications, week 88.18, 29 22 PCT Filed: Nov. 2, 1994 Jun. 1988, 88-122648/18. 86 PCT No.: PCTAJP94/01855 Primary Examiner-Mukund J. Sham Assistant Examiner-Pavanaram K. Sripada S371 Date: Mar 21, 1995 Attorney, Agent, or Firm-Sughrue. Mion. Zinn. Macpeak S 102(e) Date: Mar. 21, 1995 & Seas, PLLC 87 PCT Pub. No.: WO95/12601 57 ABSTRACT Crystalline sodium 20-methyl-2B-(1,2,3-triazol-1-yl) PCT Pub. Date: May 11, 1995 -methylpenan-3o-carboxylate-1,1-dioxide monohydrate 30 Foreign Application Priority Data (crystalline tazobactam sodium monohydrate) obtainable by adding to a concentrated aqueous solution of sodium Nov. 6, 1993 EP European Pat. Off. .............. 93.18.016 20-methyl-23-(1,2,3-triazol-1-yl)-methylpenam-30 (51) Int. Cl. ... ... CO7D 499/00; A61K 31/425 carboxylate-1,1-dioxide (tazobactam sodium) a solvent 52) U.S. Cl. ............................................ 540/310: 514/210 selected from acetone and ethanol in an amount correspond 58) Field of Search .............................. 540/310; 514/210 ing to a solvent to water ratio of between about 95:5 and 99:1 v/v and crystallizing the desired product from the solvent 56) References Cited mixture.
    [Show full text]
  • The New Fifth-Generation Cephalosporins – a Balance Between Safety and Efficacy
    REVIEWS Ref: Ro J Pharm Pract. 2020;13(3) DOI: 10.37897/RJPhP.2020.3.2 The new fifth-generation cephalosporins – a balance between safety and efficacy Aura Rusu1, Ioana-Andreea Lungu2 1 Pharmaceutical and Therapeutical Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania 2 Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania Abstract Cephalosporins are beta-lactam antibiotics classified into five generations. The newest generation has three representa- tives: ceftaroline fosamile, the combination ceftolozane/tazobactam (cephalosporin/beta-lactamase inhibitor), and ceftobi- prole medocaril. These new cephalosporins are valuable anti-infective agents, with potent activity against multidrug-re- sistant bacteria, and with a positive balance between benefits and side effects. However, the fifth-generation cephalosporins should be judiciously used to prevent the occurrence of bacterial resistance phenomenon. Keywords: cephalosporins, ceftaroline, ceftolozane, ceftobiprole, MRSA, community-acquired pneumonia, complicated skin and soft tissue infections INTRODUCTION emerged as a result of increased only, in the situation where other Cephalosporins (CFs) are beta- bacterial resistance to classical antibacterial drugs were not lactam antibiotics with numerous antibiotics. Based on the efficient. representatives widely used in the antimicrobial activity, the CFs are therapy
    [Show full text]
  • Antimicrobial Composition
    Europa,schesP_ MM M II M MM 1 1 M Ml MM M Ml J European Patent Office .ha no © Publication number: 0 384 41 OBI Office europeen, desJ brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 17.05.95 © Int. CI.6: A61 K 31/545, A61 K 31/43, //(A61K31/545,31:43) © Application number: 90103266.4 @ Date of filing: 20.02.90 The file contains technical information submitted after the application was filed and not included in this specification © Antimicrobial composition. ® Priority: 21.02.89 JP 41286/89 9-1, Kamimutsuna 3-chome 14.04.89 JP 94460/89 Okazaki-shi, Aichi (JP) @ Date of publication of application: Inventor: Sanada, Mlnoru, c/o BANYU PHARM. 29.08.90 Bulletin 90/35 CO., LTD. OKAZAKI RES. LABORATORY, © Publication of the grant of the patent: 9-1, Kamimutsuna 3-chome 17.05.95 Bulletin 95/20 Okazaki-shi, Aichi (JP) © Designated Contracting States: Inventor: Nakagawa, Susumu, c/o BANYU CH DE FR GB IT LI NL PHARM. CO., LTD. OKAZAKI RES. LABORATORY, © References cited: 9-1, Kamimutsuna 3-chome EP-A- 0 248 361 Okazaki-shi, Aichi (JP) UNLISTED DRUGS, vol. 37, no. 2, February Inventor: Tanaka, Nobuo, c/o BANYU PHARM. 1985, Chatham, New Jersey, US; "Zienam CO., LTD. 250". 2-3, Nihonbashi Honcho 2-chome Chuo-ku, © Proprietor: BANYU PHARMACEUTICAL CO., Tokyo (JP) LTD. Inventor: Inoue, Matsuhisa 2-3, Nihonbashi Honcho 2-chome 3076-3, Oaza-Tokisawa 00 Chuo-ku, Tokyo (JP) Fujlmi-mura, Seta-gun, @ Inventor: Matsuda, Kouji, c/o BANYU PHARM. Gunma (JP) CO., LTD.
    [Show full text]
  • Separation and Purification of Pharmaceuticals and Antibiotics [Table IX-1-1] Principal Antibiotics Penicillin-G (Benzylpenicillin), Oxacillin, Chlox- 1
    Separation and Purification of Pharmaceuticals and Antibiotics [Table IX-1-1] Principal Antibiotics Penicillin-G (benzylpenicillin), Oxacillin, Chlox- 1. Antibiotics acillin, Dichloxacillin, Nafcillin, Methicillin, (1) Outline Amoxicillin, Ampicillin, Ticarcillin, Piperacillin, Penicillins aspoxicillin, Antibiotics are "chemical substances produced by microorganisms Ciclacillin, Sulbenicillin, Talampicillin, which, in minute quantities, inhibit or suppress the proliferation of other Bacampicillin, Pivmecillinam, lenampicillin, microorganisms". This is defined in 1942 by Selman Abraham Waksman β-Lactams Phenethicillin, Carbenicillin etc, in the USA. Antibiotics were developed in Britain following the discovery Cephalosporin C of Penicillin in 1929 by Alexander Fleming: He found that Blue mold, Cefazolin, Cefatrizine, Cefadroxil, Cefalexin, Cephalosporins Cefaloglycin, Cefalothin, Cefaloridine, Cefoxitin, Penicillium, dissolves Staphylococcus staphylococci and inhibits its Cefotaxime, Cefoperazone, Ceftizoxime, Cefmet- growth and he named the extract from Penicillium as Penicillin. Many azole, Cefradine, Cefroxadine etc. new antibiotics have been found since 1940’s, and there are more than Other β-lactams 1,500 antibiotics. Principal ones are listed in Table IX-1-1. Kanamycins Amikacin, Kanamycin, Dibekacin Most of these antibiotics are manufactured by fermentation or by Gentamycins, Gentamicin, Micronomicin semi-synthesis that combines fermentation and organic synthesis, though Sisomycins chloramphenicol is by synthesis. Fermentation is carried out by Acti- Streptomycins Streptomycin Aminoglycosides nomycetes, mold (hyphomycetes) or bacteria in culture media with glu- Spectinomycins Spectinomycin cose, sucrose, lactose, starch or dextrin as carbon source, with nitrate, Fradiomycins Fradiomycin, ammonium salt, corn steep liquor, peptone, meat extract or yeast extract Astromicins Astromicin as nitrogen source and with a little amount of inorganic salts. Erythromycin, Oleandomycin, Carbomycin, Penicillin-type antibiotics are manufactured by semi-synthesis, i.e.
    [Show full text]
  • Analysis of Amoxicillin and Clavulanic Acid by UPLC-MS/MS in Human Plasma for Pharmacokinetic Application
    JOURNAL OF MODERN DRUG DISCOVERY AND DRUG DELIVERY RESEARCH Journal homepage: http://scienceq.org/Journals/JMDDR.php Research Article Open Access Analysis of Amoxicillin and Clavulanic Acid by UPLC-MS/MS in Human Plasma for Pharmacokinetic Application Darshan V. Chaudhary1, Daxesh P. Patel1, Jaivik V. Shah1, Priyanka A. Shah1, Vijay R. Patel2, Pranav S. Shrivastav1* 1. Department of Chemistry, School of Sciences, Gujarat University, Navrangpura, Ahmedabad- 380009, India . 2. Shri R. K Parikh Arts & Science College, Petlad-388450, Gujarat, India. *Corresponding author: Pranav S. Shrivastav, Tel.: +91-9925471963, E-mail: [email protected] Received: January 2, 2015, Accepted: February 5, 2015 Published: February 6, 2015. ABSTRACT A bioanalytical method for the simultaneous quantification of amoxicillin (AMX) and clavulanic acid (CLV) in human plasma using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) has been successfully developed and validated. The analytes and amoxicillin-d4 as internal standard were extracted from 100 µL plasma by solid phase extraction using Phenomenex Strata-X cartridges. Chromatographic separation was done on UPLC BEH C18 (50 mm × 2.1 mm, 1.7 µm) column using acetonitrile: 2.0 mM ammonium formate in water (85:15, v/v) as the mobile phase at a flow rate of 0.400 mL/min under isocratic condition. Mass spectrometric detection was by multiple reaction monitoring with an electrospray ionization source in the negative ionization mode. The response of the method was linear in the analytical range of 10.0-10000 (r2 ≥ 0.9997) and 2.5-2500 ng/mL (r2 ≥ 0.9993) for AMX and CLV respectively. Intra- and inter batch accuracy and precision (% CV) were in the range of 96.1-103.2 % and 1.48-5.88 respectively for both the analytes.
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]
  • Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
    WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) Critically Important Antimicrobials for Human Medicine 5th Revision 2016 Ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use Critically important antimicrobials for human medicine – 5th rev. ISBN 978-92-4-151222-0 © World Health Organization 2017, Updated in June 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/ igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Critically important antimicrobials for human medicine – 5th rev. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]